| OABLB0102 | Clinical outcomes by HIV serostatus, CD4 count, and viral suppression among people hospitalized with COVID-19 in the Bronx, New York | Oral abstract session with live Q&A | B69 |
| OABLB0101 | Safety, pharmacokinetics and efficacy of low-dose E/C/F/TAF in virologically suppressed children '¥2 years old living with HIV | Oral abstract session with live Q&A | B50 |
| OAB0706 | Plasma exposure-viral load response analysis for dolutegravir in children with HIV-1: Results from IMPAACT P1093 | Oral abstract session with live Q&A | B48 |
| OAB0705 | Rates of cervical lesions by age and previous screening status and enhancing treatment among women living with HIV (WLHIV) in sub-Saharan Africa within the Go Further partnership | Oral abstract session with live Q&A | B14 |
| OAB0704 | Biomarker assessment of infant adherence to isoniazid prophylaxis in a primary TB infection prevention trial in Kenya | Oral abstract session with live Q&A | B55 |
| OAB0703 | Improving pediatric index testing: Data from 12 PEPFAR-supported countries in sub-Saharan Africa | Oral abstract session with live Q&A | B47 |
| OAB0702 | Overlapping significant life events are associated with HIV viral non-suppression among youth in clinics in rural East Africa | Oral abstract session with live Q&A | B51 |
| OAB0606 | Improved metabolic parameters after switching from TAF-based 3- or 4-drug regimen to the 2-drug regimen of DTG/3TC (dolutegravir/lamivudine): The TANGO study | Oral abstract session with live Q&A | B32 |
| OAB0605 | Weight changes after switching to doravirine/lamivudine/TDF in the DRIVE-SHIFT trial | Oral abstract session with live Q&A | B22 |
| OAB0604 | Weight gain before and after switch from TDF to TAF | Oral abstract session with live Q&A | B22 |